Skip to main content
. 2021 Apr 23;28:10732748211001796. doi: 10.1177/10732748211001796

Table 1.

Base-Case Results.

Base case Comparator
Treatments Dasatinib Nilotinib
Expected annual cost $64,045.02 $58,695.35
Patient success (MMR/CCyR) 0.28 0.55
CE ratio $228,732 $107,688
Incremental cost −$5,349.67
Incremental effect 0.27
ICER −$20,183.48